Law360, New York (October 23, 2009, 5:58 PM ET) -- Novartis Pharmaceutical Corp. has lost the bellwether trial over its bone cancer drug Zometa, with a Montana jury awarding $3.2 million to a woman who accused the company of failing to adequately warn doctors of the drug's link to jaw deterioration.
After a five-day trial and eight hours of deliberation, a jury in the Missoula County District Court on Wednesday handed down its verdict in favor of Peggy Stevens, 57, who alleged she developed osteonecrosis of the jaw, or ONJ, after taking Zometa from April 2002...
Novartis Loses First Zometa Trial, Must Pay $3.2M
To view the full article, take a free trial now.
